Clinical Trial

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Study acronym: DLLEVATE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Protocol Amendment History 4 changes
notable Trial sites expanded: 66 -> 76 locations 2026-07-16
notable Trial sites expanded: 56 -> 66 locations 2026-06-24
notable Trial sites expanded: 34 -> 56 locations 2026-05-15
notable Trial sites expanded: 14 -> 34 locations 2026-04-24
Trial Details
NCT Number NCT07218146
Lead Sponsor Zai Lab (Shanghai) Co., Ltd.
Collaborators: Zai Lab (US) LLC
Conditions Small-cell Lung Cancer
Enrollment 480 participants
Start Date 2025-11-30
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20